Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice.
Acute Kidney Injury
/ etiology
Animals
Antineoplastic Agents
/ toxicity
Apoptosis
Ataxia Telangiectasia Mutated Proteins
/ antagonists & inhibitors
Cell Cycle Checkpoints
Cisplatin
/ toxicity
DNA Repair
Mice
Morpholines
/ pharmacology
Mutant Proteins
/ antagonists & inhibitors
Mutation
Phosphorylation
Pyrones
/ pharmacology
Signal Transduction
Tumor Suppressor Protein p53
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 03 2020
10 03 2020
Historique:
received:
15
09
2019
accepted:
27
02
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
24
11
2020
Statut:
epublish
Résumé
The DNA damage response after kidney injury induces cell cycle arrest in renal tubular epithelial cells, resulting in the secretion of pro-fibrotic cytokines, thereby promoting interstitial fibrosis in a paracrine manner. Phosphorylation of ataxia-telangiectasia mutated (ATM) is the initial step in the DNA damage response and subsequent cell cycle arrest; however, the effects of ATM inhibition on the injured kidney have not been explored. Pharmacological ATM inhibition by KU55933 in cisplatin-treated mice did not ameliorate, but instead exacerbated cisplatin-induced DNA damage and tubular injury, thereby increasing mortality. Analysis of isolated tubular epithelia by FACS from bigenic SLC34a1-CreERt2; R26tdTomato proximal tubular-specific reporter mice revealed that KU55933 upregulated p53 and subsequent pro-apoptotic signaling in tubular epithelia of cisplatin-treated mice, leading to marked mitochondrial injury and apoptosis. In addition, KU55933 attenuated several DNA repair processes after cisplatin treatment, including single-strand DNA repair and Fanconi anemia pathways, suggesting that DNA repair after dual treatment of cisplatin and KU55933 was not sufficient to prevent the cisplatin-induced tubular injury. Our study suggested that ATM inhibition does not increase DNA repair after cisplatin-induced DNA damage and exacerbates tubular injury through the upregulation of p53-dependent pro-apoptotic signaling. Acute kidney injury must be carefully monitored when ATM inhibitors become available in clinical practice in the future.
Identifiants
pubmed: 32157166
doi: 10.1038/s41598-020-61456-7
pii: 10.1038/s41598-020-61456-7
pmc: PMC7064514
doi:
Substances chimiques
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one
0
Antineoplastic Agents
0
Morpholines
0
Mutant Proteins
0
Pyrones
0
Trp53 protein, mouse
0
Tumor Suppressor Protein p53
0
ATM protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4441Références
Kidney Int. 2004 Jul;66(1):196-202
pubmed: 15200426
Oncotarget. 2017 Dec 11;9(4):4318-4337
pubmed: 29435105
Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658
pubmed: 30023007
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1527-32
pubmed: 24127583
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
J Am Soc Nephrol. 2010 Jan;21(1):31-41
pubmed: 19892935
DNA Repair (Amst). 2016 Feb;38:84-93
pubmed: 26686657
J Biol Chem. 2010 Oct 22;285(43):33010-7
pubmed: 20709753
Kidney Int. 2013 Sep;84(3):457-67
pubmed: 23636171
Nat Med. 2010 May;16(5):535-43, 1p following 143
pubmed: 20436483
J Am Soc Nephrol. 2017 Mar;28(3):776-784
pubmed: 27624490
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Cancer Res. 2008 Sep 15;68(18):7466-74
pubmed: 18794134
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302
pubmed: 12370430
Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49
pubmed: 27145721
Cardiovasc Res. 2016 May 1;110(1):85-95
pubmed: 26862121
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Biochim Biophys Acta. 2014 Jul;1842(7):1088-96
pubmed: 24726884
Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355
pubmed: 28984489
J Am Soc Nephrol. 2016 Mar;27(3):687-97
pubmed: 26519085
Cancer Res. 2004 Dec 15;64(24):9152-9
pubmed: 15604286
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e478s
pubmed: 30208165
Semin Nephrol. 2003 Sep;23(5):460-4
pubmed: 13680535
Pharmacol Ther. 2015 May;149:124-38
pubmed: 25512053
Cell. 2012 Jun 22;149(7):1536-48
pubmed: 22726440
Cell Cycle. 2014;13(22):3541-50
pubmed: 25483091
Nat Rev Nephrol. 2015 May;11(5):264-76
pubmed: 25643664
Nat Commun. 2017 Apr 24;8:15104
pubmed: 28436431
Nat Genet. 2003 Jan;33(1):80-4
pubmed: 12447371
J Clin Invest. 2019 Nov 1;129(11):4797-4816
pubmed: 31589169
J Am Soc Nephrol. 2001 May;12(5):900-8
pubmed: 11316848
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674655
Science. 1998 Sep 11;281(5383):1674-7
pubmed: 9733514
Nat Rev Genet. 2007 Oct;8(10):735-48
pubmed: 17768402
Annu Rev Biochem. 2015;84:711-38
pubmed: 25580527
BMC Cancer. 2017 Feb 20;17(1):144
pubmed: 28219368
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
Nature. 2013 Jan 17;493(7432):356-63
pubmed: 23325218
Kidney Int. 2012 Mar;81(5):442-8
pubmed: 22113526
J Am Soc Nephrol. 2014 Oct;25(10):2278-89
pubmed: 24700871
Kidney Int. 2012 Sep;82(5):516-24
pubmed: 22673882
Nat Protoc. 2006;1(1):23-9
pubmed: 17406208
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
Nat Commun. 2013;4:2308
pubmed: 23917356
J Am Soc Nephrol. 2001 May;12(5):983-92
pubmed: 11316857
J Am Soc Nephrol. 2009 Aug;20(8):1754-64
pubmed: 19470675
J Am Soc Nephrol. 2019 Jan;30(1):23-32
pubmed: 30510133
Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69
pubmed: 18813293
J Am Soc Nephrol. 2014 Dec;25(12):2707-16
pubmed: 24854277
Mol Cell Biol. 2004 Jul;24(14):6430-44
pubmed: 15226443
Mol Cancer Ther. 2013 Jun;12(6):959-67
pubmed: 23512991
Nat Rev Cancer. 2002 Aug;2(8):594-604
pubmed: 12154352
Nat Med. 2018 Jul;24(7):947-953
pubmed: 29892060
Cell. 2002 May 17;109(4):459-72
pubmed: 12086603
Biochem Pharmacol. 2005 Dec 5;70(12):1823-31
pubmed: 16242669